Medistim (MEDI) Q2 2026 earnings summary

Executive summary

• Achieved record sales and EBIT for Q2 and H1 2026, with Q2 revenue at NOK 202 million (up 19.5% YoY) and H1 at NOK 403.7 million (up 15.1% YoY), despite negative currency effects.

• Own products drove growth, with strong contributions from Americas (up 46.3% currency-neutral in Q2), EMEA, and APAC.

• EBIT margin reached 32.3% in Q2 and 30.3% for H1, reflecting strong operational leverage.

• Dividend of NOK 8 per share (NOK 146.3 million) paid in May; board proposes quarterly dividends going forward.

• Recurring sales remained high at 67–70% of total sales in H1.

Financial highlights

• Q2 revenue: NOK 202 million (up 19.5% YoY); H1 revenue: NOK 403.7 million (up 15.1% YoY).

• Q2 EBIT: NOK 65.3 million (32.3% margin); H1 EBIT: NOK 122.4 million (30.3% margin).

• Q2 EBITDA: NOK 71.3 million (35.3% margin); H1 EBITDA: NOK 134.6 million.

• Q2 net profit: NOK 52.2 million; H1 net profit: NOK 92.5 million.

• Gross margin Q2: 82.2% (up from 81.9%); H1: 80.9% (down from 82.5%).

Outlook and guidance

• Updated long-term outlook expects higher growth trajectory and continued margin expansion through 2030, targeting NOK 1 billion annual revenue within a few years.

• Growth drivers include new product launches (MiraQ Ultimate, MiraQ Vascular), expanded sales force, and increased clinical adoption.

• Significant market opportunity remains, with only 10% of estimated NOK 7 billion market addressed and 40% penetration in CABG procedures.

• All projections subject to uncertainty and not formal guidance.